Shannon N. Westin, MD, MPH - New Horizons for Advanced Endometrial Cancer Treatment: Utilizing Innovative Immunotherapies and Other Novel Approaches

Go online to PeerView.com/GEP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For patients with recurrent or advanced endometrial cancer, tremendous therapeutic gains have been realized with the incorporation of immune checkpoint inhibitors. Monotherapy and combination approaches have had multiple regulatory approvals in the second-line setting and clinical trials assessing use in the frontline setting are underway. In this CME activity, an expert shares scientific rationale and practical guidance for incorporating molecular testing into patient management to personalize therapeutic selection. Pairing in-depth updates on efficacy and safety data for immunotherapeutic and other novel regimens with case-based discussions of best practices for bringing individualized treatment plans to the clinic, this is a learning opportunity for all in the field of gynecologic oncology. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence of immunotherapy-based options, among other novel therapies, for patients with recurrent or advanced endometrial cancer; Integrate new and emerging therapeutic options into personalized treatment plans for patients with recurrent or advanced endometrial cancer, taking into consideration the latest available evidence, current guideline recommendations, and biomarker testing results; and Apply proactive, collaborative strategies to mitigate and manage adverse events in patients with recurrent and advanced endometrial cancers who are receiving novel therapies as part of their care]